The specific objectives comprise: (1) evaluating the effects of EVO on the synthesis and metabolism of arginine in CRC cells, as well as its role in inhibiting cell proliferation and migration; (2) investigating the modulation of ASS1 expression by EVO via the Wnt/β-catenin/c-MYC signaling pathway; and (3) confirming EVO’s regulatory effects on the growth of CRC allografts and arginine metabolism by utilizing animal models, thereby offering experimental backing for potential clinical applications. This evidence concerns the gene ASS1 and colorectal carcinoma.